Manufacturer record
Inducare Pharmaceutical and Research Foundatiion: regulatory record
Last checked 10 October 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by Inducare Pharmaceutical and Research Foundatiion (Maharashtra) were declared Not of Standard Quality between August 2026 and August 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
4 records linked to Inducare Pharmaceutical and Research Foundatiion in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Rosuvastatin Tablets IP 5mg | IT04501Mfg 2025-07 · Exp 2025-06 | The sample does not comply with IP requirements for the dissolution test, The Sample is Declared As Misbranded Vide Rule 96 Section 17(b) and 127, of Drugs And Cosmetics Act, 1940 And Rules 1945, as the Manufacturer does not stated name of the Colour used, in the Composition of Sample, on the Sample blisters and carton and Mfg. Date is not mentioned on the Sample BlistersDissolution | FDAL, MumbaiState lab | Aug 2026 |
| Metronidazole Tablets IP 400mg | IT6050Mfg 2026-02 · Exp 2029-01 | 1.The Content of Metronidazole in the Sample is less (i.e. 32.44% of stated Amount) the I.P. Limits. (I.P. Limit: Not less than 90% and not more than 110% of stated Amount). 2. The Sample does not Comply with IP requirements for the Dissolution Test. The Sample is declared as Misbranded Vide Rule 96: Section 17(c) of the Drugs and Cosmetics Act 1940 and Rules 1945, as Manufacturer has stated, 1.Tablets are film Coated but, the Tablets are found uncoated. 2. Each Film Coated Tablet contains: Metronidazole Tablets IP 400 mg, Instead of Metronidazole IP400 mg.Dissolution | FDAL, MumbaiState lab | Aug 2026 |
| Metronidazole Tablets IP 200mg | IT6151Mfg 2026-02 · Exp 2029-01 | 1. Content of Metronidazole in the Sample is less (i.e. 52.75% of stated Amount) than the I.P. Limits. (I.P. Limit: Not less than 90% and not more than 110% of stated Amount). 2.The Sample does not Comply with IP requirements for the Dissolution Test. The Sample is declared as Misbranded Vide Rule 96: Section 17(c) of the Drugs and Cosmetics Act 1940 and Rules 1945, as Manufacturer has stated, The Tablets are film Coated but, the Tablets are found uncoated.Dissolution | FDAL, MumbaiState lab | Aug 2026 |
| Domperidone Tablets IP 10mg | IT14501Mfg 2025-09 · Exp 2028-08 | The Sample Does Not Comply With IP requirements for the Dissolution test. The Sample is Declared As Misbranded Vide Rule 96 Section 17(b) and (c), of Drugs And Cosmetics Act, 1940 And Rules 1945, as the Manufacturing details about Mfg. Date and Exp. Date mentioned on Sample Carton and Sample Strips are different. Also Manufacturer mentioned name of Active Ingredients as Domperidone instead of Domperidone Maleate Equivalent to Domperidone.Dissolution | FDAL, MumbaiState lab | Aug 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.